Heart failure remains a major unmet medical need. To facilitate the identification of molecules with the most desirable efficacy profile, AnaBios developed a human cardiomyocyte contractility assay for the identification of positive inotropes with the potential to correct contractility deficits in heart failure. This adult human primary cardiomyocyte-based platform will facilitate the identification of molecules with the most desirable pharmacological correction of specific forms of contractility deficit.

AUTHORS: Najah Abi-Gerges, Tim Indersmitten, Ky Truong, William Nguyen, Ismael Tapia, Nathalie Nguyen, Guy Page, Paul E Miller and Andre Ghetti